Factors associated with OS (multivariable analysis on imputed datasets)
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| Age at transplant | ||
| (0,10) | 1 | — |
| (10,20) | 1.39 (1.07-1.80) | .013 |
| (20,50) | 1.92 (1.25-2.94) | .003 |
| Donor/recipient sex | ||
| Female/female | 1 | — |
| Female/male | 0.86 (0.60-1.22) | .39 |
| Male/female | 1.01 (0.71-1.43) | .96 |
| Male/male | 0.84 (0.61-1.16) | .29 |
| Donor/recipient CMV status | ||
| Negative/negative | 1 | — |
| Negative/positive | 2.11 (1.34-3.33) | .001 |
| Positive/negative | 1.52 (0.93-2.50) | .096 |
| Positive/positive | 1.68 (1.10-2.57) | .016 |
| Time from diagnosis to transplant | ||
| ≤12 mo | 1 | — |
| >12 mo | 1.55 (1.14-2.12) | .005 |
| Donor | ||
| HLA-identical sibling | 1 | — |
| HLA-matched unrelated* | 1.57 (1.19-2.08) | .002 |
| Bone marrow status at SCT | ||
| AA | 1 | — |
| MDS/AML | 2.10 (1.41-3.11) | .0002 |
| Stem cell source | ||
| BM | 1 | — |
| PB | 1.15 (0.82-1.62) | .42 |
| SCT date | ||
| 1972-1999 | 1 | — |
| 2000-2009 | 0.80 (0.54-1.16) | .24 |
| Fludarabine in conditioning | ||
| No | 1 | — |
| Yes | 0.40 (0.26-0.64) | <.0001 |
| ATG in conditioning | ||
| No | 1 | — |
| Yes | 1.19 (0.89-1.58) | .24 |
| Irradiation | ||
| No | 1 | — |
| TAI/TLI/TBI* | ||
| 0-1 y posttransplant | 0.81 (0.53-1.23) | .32 |
| 1-5 y posttransplant | 1.11 (0.45-2.73) | .83 |
| >5 y posttransplant | 5.69 (1.48-21.8) | .011 |
| Ex-vivo T-cell manipulation | ||
| No | 1 | — |
| Yes | 1.40 (0.94-2.09) | .10 |
| Time-dependent variables | ||
| Chronic GVHD | 3.10 (2.18-4.39) | <.0001 |
| Secondary malignancy | 23.0 (13.3-40.1) | <.0001 |
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| Age at transplant | ||
| (0,10) | 1 | — |
| (10,20) | 1.39 (1.07-1.80) | .013 |
| (20,50) | 1.92 (1.25-2.94) | .003 |
| Donor/recipient sex | ||
| Female/female | 1 | — |
| Female/male | 0.86 (0.60-1.22) | .39 |
| Male/female | 1.01 (0.71-1.43) | .96 |
| Male/male | 0.84 (0.61-1.16) | .29 |
| Donor/recipient CMV status | ||
| Negative/negative | 1 | — |
| Negative/positive | 2.11 (1.34-3.33) | .001 |
| Positive/negative | 1.52 (0.93-2.50) | .096 |
| Positive/positive | 1.68 (1.10-2.57) | .016 |
| Time from diagnosis to transplant | ||
| ≤12 mo | 1 | — |
| >12 mo | 1.55 (1.14-2.12) | .005 |
| Donor | ||
| HLA-identical sibling | 1 | — |
| HLA-matched unrelated* | 1.57 (1.19-2.08) | .002 |
| Bone marrow status at SCT | ||
| AA | 1 | — |
| MDS/AML | 2.10 (1.41-3.11) | .0002 |
| Stem cell source | ||
| BM | 1 | — |
| PB | 1.15 (0.82-1.62) | .42 |
| SCT date | ||
| 1972-1999 | 1 | — |
| 2000-2009 | 0.80 (0.54-1.16) | .24 |
| Fludarabine in conditioning | ||
| No | 1 | — |
| Yes | 0.40 (0.26-0.64) | <.0001 |
| ATG in conditioning | ||
| No | 1 | — |
| Yes | 1.19 (0.89-1.58) | .24 |
| Irradiation | ||
| No | 1 | — |
| TAI/TLI/TBI* | ||
| 0-1 y posttransplant | 0.81 (0.53-1.23) | .32 |
| 1-5 y posttransplant | 1.11 (0.45-2.73) | .83 |
| >5 y posttransplant | 5.69 (1.48-21.8) | .011 |
| Ex-vivo T-cell manipulation | ||
| No | 1 | — |
| Yes | 1.40 (0.94-2.09) | .10 |
| Time-dependent variables | ||
| Chronic GVHD | 3.10 (2.18-4.39) | <.0001 |
| Secondary malignancy | 23.0 (13.3-40.1) | <.0001 |
Nonproportional hazards were found (P = .028). An average adjusted effect of HLA-matched unrelated donor over the follow-up time is presented. Time-varying hazard ratios were 2.15 (95% CI, 1.57-2.95) 0-1 y post-SCT, 0.78 (95% CI, 0.36-1.68) 1-5 y post-SCT, and 0.37 (95% CI, 0.17-0.82) more than 5 y post-SCT.